Literature DB >> 9700510

Structure-function studies of T-cell receptor-superantigen interactions.

H Li1, A Llera, R A Mariuzza.   

Abstract

Superantigens (SAGs) are a class of disease-causing and immunostimulatory proteins of bacterial or viral origin that activate T cells by binding to the V beta domain of the T-cell antigen receptor (TCR). The three-dimensional structure of the complex between a TCR beta chain (mouse V beta 8.2-J beta 2.1-C beta 1) and the SAG staphylococcal enterotoxin C3 (SEC3) has been recently determined. The complementarity-determining region 2 (CDR2) of the beta chain and, to lesser extents, CDR1 and hypervariable region 4 (HV4) bind in a cleft between the small and large domains of the SAG. A model of the TCR-SAG-peptide/MHC complex constructed from available crystal structures reveals how the SAG acts as a wedge between the TCR and MHC, thereby displacing the antigenic peptide away from the TCR and circumventing the normal mechanism for T-cell activation by peptide/MHC. To evaluate the actual contribution of individual SAG residues to stabilizing the V beta C beta-SEC3 complex, as well as to investigate the relationship between the affinity of SAGs for TCB and MHC and their ability to activate T cells, we measured the binding of a set of SEC3 mutants to a soluble recombinant TCR beta chain and to the human MHC class II molecule HLA-DR1. We show that there is direct correlation between affinity and ability to stimulate T cells, with SAGs having the highest affinity for the TCR being the most biologically active. We also find that there is an interplay between TCR-SAG and SAG-MHC interactions in determining mitogenic potency, such that a small increase in the affinity of a SAG for MHC can overcome a large decrease in the SAG's affinity for the TCR. Finally, we observe that those SEC3 residues that make the greatest energetic contribution to stabilizing the V beta C beta-SEC3 complex are strictly conserved among enterotoxins reactive with mouse V beta 8.2, thereby explaining why SAGs having other residues at these positions show different V beta-binding specificities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9700510     DOI: 10.1111/j.1600-065x.1998.tb01196.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  9 in total

1.  Peptide antagonists of superantigen toxins.

Authors:  Raymond Kaempfer
Journal:  Mol Divers       Date:  2004       Impact factor: 2.943

2.  Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors.

Authors:  A C Papageorgiou; C M Collins; D M Gutman; J B Kline; S M O'Brien; H S Tranter; K R Acharya
Journal:  EMBO J       Date:  1999-01-04       Impact factor: 11.598

3.  Specific inhibitory action of anisodamine against a staphylococcal superantigenic toxin, toxic shock syndrome toxin 1 (TSST-1), leading to down-regulation of cytokine production and blocking of TSST-1 toxicity in mice.

Authors:  Saori Nakagawa; Koji Kushiya; Ikue Taneike; Ken'ichi Imanishi; Takehiko Uchiyama; Tatsuo Yamamoto
Journal:  Clin Diagn Lab Immunol       Date:  2005-03

4.  High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence.

Authors:  Yimeng Wang; Christopher Sundling; Richard Wilson; Sijy O'Dell; Yajing Chen; Kaifan Dai; Ganesh E Phad; Jiang Zhu; Yongli Xiao; John R Mascola; Gunilla B Karlsson Hedestam; Richard T Wyatt; Yuxing Li
Journal:  J Immunol       Date:  2016-03-21       Impact factor: 5.422

5.  Healthcare- and Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) and Fatal Pneumonia with Pediatric Deaths in Krasnoyarsk, Siberian Russia: Unique MRSA's Multiple Virulence Factors, Genome, and Stepwise Evolution.

Authors:  Olga E Khokhlova; Wei-Chun Hung; Tsai-Wen Wan; Yasuhisa Iwao; Tomomi Takano; Wataru Higuchi; Svetlana V Yachenko; Olga V Teplyakova; Vera V Kamshilova; Yuri V Kotlovsky; Akihito Nishiyama; Ivan V Reva; Sergey V Sidorenko; Olga V Peryanova; Galina V Reva; Lee-Jene Teng; Alla B Salmina; Tatsuo Yamamoto
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

Review 6.  FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights.

Authors:  Teresa Krakauer
Journal:  Immunotargets Ther       Date:  2017-05-02

Review 7.  What's new in the aetiopathogenesis of vasculitis?

Authors:  Paul A Brogan
Journal:  Pediatr Nephrol       Date:  2007-03-15       Impact factor: 3.714

Review 8.  Community-acquired methicillin-resistant Staphylococcus aureus: community transmission, pathogenesis, and drug resistance.

Authors:  Tatsuo Yamamoto; Akihito Nishiyama; Tomomi Takano; Shizuka Yabe; Wataru Higuchi; Olga Razvina; Da Shi
Journal:  J Infect Chemother       Date:  2010-03-25       Impact factor: 2.211

9.  Secondary mechanisms of diversification in the human antibody repertoire.

Authors:  Bryan S Briney; James E Crowe
Journal:  Front Immunol       Date:  2013-03-11       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.